Treatment & control of benign prostatic hyperplasia (BPH). Prevention of urologic events to reduce risk of acute urinary retention & surgery including transurethral resection of prostate & prostatectomy. Regression of enlarged prostate, improve urinary flow & symptoms associated w/ BPH. In combination w/ doxazosin to reduce risk of symptomatic progression of BPH.
Exclude urethral stricture, infection, cancer, hypotonic bladder & other neurogenic disorders prior to treatment. Changes in breast tissue; male breast cancer. Monitor patients w/ large residual urine vol &/or severely diminished urinary flow for obstructive uropathy. Perform digital rectal exam, serum PSA level & other evaluations for prostate cancer prior to therapy & periodically thereafter. Hepatic dysfunction. Not to be used in women & childn. Elderly >70 yr.